A national survey of barriers and facilitators to medications for opioid use disorder among legal-involved veterans in the Veterans Health Administration

References

• Binswanger IA, Blatchford PJ, Mueller SR, Stern MF. Mortality after prison release: opioid overdose and other causes of death, risk factors, and time trends from 1999 to 2009. Ann Intern Med. 2013;159(9):592–600.
   PubMed Web of Science ®Google Scholar
• Green TC, Clarke J, Brinkley-Rubinstein L, et al. Postincarceration fatal overdoses after implementing medications for addiction treatment in a statewide correctional system. JAMA Psychiatry. 2018;75(4):405–407.
   PubMed Web of Science ®Google Scholar
• Wortzel HS, Blatchford P, Conner L, Adler LE, Binswanger IA. Risk of death for veterans on release from prison. J Am Acad Psychiatry Law. 2012;40(3):348–354.
   PubMed Web of Science ®Google Scholar
• Baser O, Chalk M, Fiellin DA, Gastfriend DR. Cost and utilization outcomes of opioid-dependence treatments. Am J Manag Care. 2011; 17(Suppl 8):S235–S248.
   PubMedGoogle Scholar
• Coviello DM, Cornish JW, Lynch KG, et al. A multisite pilot study of extended-release injectable naltrexone treatment for previously opioid-dependent parolees and probationers. Subst Abus. 2012;33(1):48–59.
   PubMed Web of Science ®Google Scholar
• Gisev N, Shanahan M, Weatherburn DJ, et al. A cost-effectiveness analysis of opioid substitution therapy upon prison release in reducing mortality among people with a history of opioid dependence. Addiction. 2015;110(12):1975–1984.
   PubMed Web of Science ®Google Scholar
• Murphy SM, Polsky D. Economic evaluations of opioid use disorder interventions. Pharmacoeconomics. 2016;34(9):863–887.
   PubMed Web of Science ®Google Scholar
• Wyse JJ, Gordon AJ, Dobscha SK, et al. Medications for opioid use disorder in the Department of Veterans Affairs (VA) health care system: historical perspective, lessons learned, and next steps. Subst Abus. 2018;39(2):139–144.
   PubMed Web of Science ®Google Scholar
• U.S. Department of Veterans Affairs and Department of Defense. VA/DoD Clinical Practice Guidelines for the Management If Substance Use Disorders. Washington, DC: U.S. Department of Veterans Affairs; 2015.
   Google Scholar
• Finlay AK, Harris AHS, Timko C, et al. Disparities in access to medications for opioid use disorder in the Veterans Health Administration. J Addict Med. 2021;15(2):143–149.
   PubMed Web of Science ®Google Scholar
• Peterson JA, Schwartz RP, Mitchell SG, et al. Why don't out-of-treatment individuals enter methadone treatment programmes? Int J Drug Policy. 2010;21(1):36–42.
   PubMed Web of Science ®Google Scholar
• Tofighi B, Williams AR, Chemi C, Suhail-Sindhu S, Dickson V, Lee JD. Patient barriers and facilitators to medications for opioid use disorder in primary care. Subst Use Misuse. 2019;54(14):2409–2419.
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Kavanagh G, Krumm M, et al. Facilitators and barriers in implementing buprenorphine in the Veterans Health Administration. Psychol Addict Behav. 2011;25(2):215–224.
   PubMed Web of Science ®Google Scholar
• Mackey K, Veazie S, Anderson J, Bourne D, Peterson K. Evidence Brief: Barriers and Facilitators to Use of Medications for Opioid Use Disorder. Washington, DC: Department of Veterans Affairs (US); 2019. http://www.ncbi.nlm.nih.gov/books/NBK549203/. Accessed May 30, 2020.
   Google Scholar
• Csete J. Criminal justice barriers to treatment of opioid use disorders in the United States: the need for public health advocacy. Am J Public Health. 2019;109(3):419–422.
   PubMed Web of Science ®Google Scholar
• Reichert J, Gleicher L. Probation clients' barriers to access and use of opioid use disorder medications. Health Justice. 2019;7(1):10
   PubMedGoogle Scholar
• Finlay AK, Morse E, Stimmel M, et al. Barriers to medications for opioid use disorder among veterans involved in the legal system: a qualitative study. J Gen Intern Med. 2020;35(9):2529–2536.
   PubMed Web of Science ®Google Scholar
• Chang ET, Oberman RS, Cohen AN, et al. Increasing access to medications for opioid use disorder and complementary and integrative health services in primary care. J Gen Intern Med. 2020;35(Suppl 3):918–926.
   PubMed Web of Science ®Google Scholar
• Brunet N, Moore DT, Lendvai Wischik D, Mattocks KM, Rosen MI. Increasing buprenorphine access for veterans with opioid use disorder in rural clinics using telemedicine. Subst Abus. 2020:1–8. doi:10.1080/08897077.2020.1728466.
   PubMed Web of Science ®Google Scholar
• Blue-Howells JH, Clark SC, van den Berk-Clark C, McGuire JF. The U.S. Department of Veterans Affairs Veterans Justice programs and the sequential intercept model: case examples in national dissemination of intervention for justice-involved veterans. Psychol Serv. 2013;10(1):48–53.
   PubMed Web of Science ®Google Scholar
• Finlay AK, Harris AHS, Rosenthal J, et al. Receipt of pharmacotherapy for opioid use disorder by justice-involved U.S. Veterans Health Administration patients. Drug Alcohol Depend. 2016;160:222–226.
   PubMed Web of Science ®Google Scholar
• Green CA, McCarty D, Mertens J, et al. A qualitative study of the adoption of buprenorphine for opioid addiction treatment. J Subst Abuse Treat. 2014;46(3):390–401.
   PubMed Web of Science ®Google Scholar
• Harris AHS, Ellerbe L, Reeder RN, et al. Pharmacotherapy for alcohol dependence: perceived treatment barriers and action strategies among Veterans Health Administration service providers. Psychol Serv. 2013;10(4):410–419.
   PubMed Web of Science ®Google Scholar
• Li J, Sussell AL. Multiple Imputation of Family Income Data in the 2015 Behavioral Risk Factor Surveillance System. Cincinnati, OH: MidWest SAS® Users Group; 2017.
   Google Scholar
• von Hippel PT. How many imputations do you need? A two-stage calculation using a quadratic rule. Sociol Methods Res. 2020;49(3):699–718.
   Web of Science ®Google Scholar
• Finlay AK, Binswanger IA, Timko C, et al. Facility-level changes in receipt of pharmacotherapy for opioid use disorder: implications for implementation science. J Subst Abuse Treat. 2018;95:43–47.
   PubMed Web of Science ®Google Scholar
• Bunting AM, Oser CB, Staton M, Eddens KS, Knudsen H. Clinician identified barriers to treatment for individuals in Appalachia with opioid use disorder following release from prison: a social ecological approach. Addict Sci Clin Pract. 2018;13(1):23.
   PubMedGoogle Scholar
• Haffajee RL, Bohnert ASB, Lagisetty PA. Policy pathways to address provider workforce barriers to buprenorphine treatment. Am J Prev Med. 2018;54(6 Suppl 3):S230–S242.
   PubMed Web of Science ®Google Scholar
• Winograd RP, Presnall N, Stringfellow E, et al. The case for a medication first approach to the treatment of opioid use disorder. Am J Drug Alcohol Abuse. 2019;45(4):333–340.
   PubMed Web of Science ®Google Scholar
• Winograd RP, Wood CA, Stringfellow EJ, et al. Implementation and evaluation of Missouri's Medication First treatment approach for opioid use disorder in publicly-funded substance use treatment programs . J Subst Abuse Treat. 2020;108:55–64.
   PubMed Web of Science ®Google Scholar
• Gordon AJ, Drexler K, Hawkins EJ, et al. Stepped Care for Opioid Use Disorder Train the Trainer (SCOUTT) initiative: expanding access to medication treatment for opioid use disorder within Veterans Health Administration facilities. Subst Abus. 2020;41(3):275–282.
   PubMed Web of Science ®Google Scholar
• National Academies of Sciences, Engineering, and Medicine. Medications for Opioid Use Disorder save Lives. Washington, DC: The National Academies Press; 2019.
   Google Scholar
• Lam JA, Lee HIS, Truong AQ, et al. Brief video intervention to improve attitudes throughout medications for opioid use disorder in a correctional setting. J Subst Abuse Treat. 2019;104:28–33.
   PubMed Web of Science ®Google Scholar
• Salvador JG, Bhatt SR, Jacobsohn VC, et al. Feasibility and acceptability of an online ECHO intervention to expand access to medications for treatment of opioid use disorder, psychosocial treatments and supports. Subst Abus. 2020:1–8. doi:10.1080/08897077.2020.1806184.
   Google Scholar